Jefferies Group LLC reissued their buy rating on shares of Ra Pharmctl Inc (NASDAQ:RARX) in a research note released on Thursday. They currently have a $25.00 price target on the stock.

A number of other equities research analysts have also recently commented on the company. Zacks Investment Research cut Ra Pharmctl from a buy rating to a hold rating in a report on Thursday, June 29th. Royal Bank Of Canada assumed coverage on shares of Ra Pharmctl in a research note on Thursday, September 14th. They set an outperform rating and a $21.00 target price for the company. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $26.00.

Ra Pharmctl (RARX) opened at 14.60 on Thursday. Ra Pharmctl has a 52-week low of $12.05 and a 52-week high of $24.12. The company’s 50-day moving average is $14.70 and its 200-day moving average is $14.70. The firm’s market capitalization is $330.09 million.

Ra Pharmctl (NASDAQ:RARX) last released its earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.06). Analysts forecast that Ra Pharmctl will post ($2.31) EPS for the current fiscal year.

WARNING: This story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/10/02/ra-pharmctl-inc-rarx-given-buy-rating-at-jefferies-group-llc.html.

Several hedge funds have recently bought and sold shares of RARX. California State Teachers Retirement System increased its position in Ra Pharmctl by 26.1% in the second quarter. California State Teachers Retirement System now owns 20,800 shares of the company’s stock worth $390,000 after purchasing an additional 4,300 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Ra Pharmctl by 30.6% during the second quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock valued at $204,000 after purchasing an additional 2,543 shares in the last quarter. State Street Corp raised its stake in Ra Pharmctl by 40.3% during the second quarter. State Street Corp now owns 151,063 shares of the company’s stock valued at $2,830,000 after purchasing an additional 43,376 shares in the last quarter. Nexthera Capital LP purchased a new stake in Ra Pharmctl during the second quarter valued at $1,912,000. Finally, Fred Alger Management Inc. raised its stake in Ra Pharmctl by 83.3% during the second quarter. Fred Alger Management Inc. now owns 33,000 shares of the company’s stock valued at $618,000 after purchasing an additional 15,000 shares in the last quarter. 66.26% of the stock is owned by hedge funds and other institutional investors.

About Ra Pharmctl

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Analyst Recommendations for Ra Pharmctl (NASDAQ:RARX)

Receive News & Stock Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related stocks with our FREE daily email newsletter.